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Lymphocytic choriomeningitis (LCM) I virus, when  inoculated into  the  brains of 
adult mice, produces an acute inflammation of choroid plexus, ependyma, and lepto- 
meninges  and  a  marked  convulsive diathesis, with  death  occurring 6-8  days  after 
infection  (1,  2).  The  immunological nature  of  this disease has been  established by 
experiments utilizing a variety of immunosuppressive procedures (3-6). Immunosup- 
pressed mice are protected, often permanently, against acute central nervous system 
(CNS)  disease, and fail to show pathological evidence of choriomeningitis. Further- 
more, immunosuppression does not alter the replication of virus in the brain (4), and 
in immunosuppression-induced LCM carriers, virus titers may remain at a high levei 
for a long period (4, 5). 
To further document that acute LCM is mediated by an immunological mechanism, 
attempts  have  been  made  to  produce  disease by  adoptive immunization  of  virus 
carriers. Volkert and his associates (7,  8)  have conducted detailed studies in which 
they transferred isogenic lymphoid cells from immune donors into neonatally infected 
carriers. They showed that such transfers could suppress viremia concomitant with 
the appearance of high titers of neutralizing (N)  and complement-fixing (CF)  anti- 
bodies, However,  these successful transfers failed to produce acute CNS  disease al- 
though  there was a  marked decrease in virus titers in the brain (9).  Similar results 
have been reported by others (3,  10,  11). 
The successful production of acute LCM by adoptive inmmnization of drug- 
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induced virus carriers is reported in this paper. In the preceding report (12)  a 
comparison  was  made  of  the  distribution  of  viral  antigen  in  the  brains  of 
"neonatal" virus carriers inoculated within 24 hr of birth, and "drug-induced" 
carriers infected as adults and given a  single dose of cyclophosphamide (CY). 
Parallel transfer of immune spleen cells into these two types of carriers failed 
to cause apparent illness in neonatal carriers but regularly caused lethal chorio- 
meningitis in drug-induced carriers. The differing results with carriers produced 
in  different  ways  suggests  an  explanation  for  prior  failures,  while  the  drug- 
induced carrier provides  a  potent  experimental model for  further  analysis of 
the immunological mechanisms of classical LCM disease. 
Materials and Methods 
The virus and methods for virus titration, immunofluorescent staining, histological examina- 
tion, and complement-fixation  (CF) tests have been described previously (12). BALB/c mice 
(Flow Laboratories, Dublin, Va.) were used for all adoptive immunization experiments. 
Virus Carriers.--Neonatal carriers were mice, inoculated intracerebrally within 24 hr of 
birth with 1000 L1)50 of the E-350 strain of LCM virus and held until age 8 wk or older. Drug- 
induced carriers were 10-12-wk-old mice, inoculated intracerebrally  with 1000 LDS0 and given 
a single intraperitoneal injection of CY 150 mg/kg, 3 days later. 
Donors for Adoptive Immunization.--  Adult BALB/c mice were  given  an intraperitonea] 
injection of about 1000 LDs0 in 0.5 ml. At intervals of 1-2 wk four additional intraperitonea] 
doses of virus were administered, the last one 7-10 days before cell transfer. 
Cells for Adoptive Immunization.--Immune or normal donors were killed, spleens removed, 
and a cell suspension prepared by gently rubbing each spleen against a stainless steel mesh into 
a sterile Petri dish containing Eagle's minimal essential medium  (MEM) in Hanks' balanced 
salt solution  with penicillin  (100 units/ml) and streptomycin (0.1 mg/ml). After removing 
rapidly settling clumps from  the suspension,  the cells were washed  once in MEM and sus- 
pended in a volume of 1 ml/spleen, equivalent to about 2  )<  108 nucleated cells/ml. About 
70% of these cells were viable, by the trypan blue exclusion test. For adoptive immunization 
of virus carriers a standard dose of one spleen equivalent was injected intraperitoneally. 
Immune Mouse Serum.--Serum was prepared by pooling blood from mice immunized  as 
donors for adoptive immunization,  obtained when animals were killed for spleen cells. It was 
inactivated at 56°C for 30 rain, and administered undiluted, 0.25 ml/mouse, by tail vein in- 
jection. 
RESULTS 
Adoptive Immunization with Spleen Cells 
Drug-I~duced  Adult  Carriers.--When  adult  BALB/c  mice  were  given  a 
single dose of CY, 150 rng/kg, 3 days after an intracerebral inoculation of 1000 
LDs0 of LCM virus, approximately 90 %  became virus carriers, while 10 %  died 
of choriomeningitis about  2  wk  after  infection  (12).  Carrier mice  were  givert 
2 X  l0  s spleen cells from immune donors, at 5-25 days after infection (Table I). 
When  cells were  transferred  from  5-9  days  after  infection,  mice  consistently 
died with symptoms typical of acute choriomeningitis. Illness usually began 2 
days before death with onset of hunched  posture,  ruffled fur,  and generalized 
tremulousness.  Subsequently,  many  animals developed convulsions,  and  dead 876  PATHOGENESIS  OF  LYMPHOCYTIC  CHORIOMENINGITIS.  II 
animals were often found in the characteristic terminal posture with front legs 
flexed  and hind legs extended. The median interval to death was 6 days after 
cell  transfer.  When immune cells were transferred  17-25 days after infection, 
all mice developed symptoms of acute LCM, but mortality varied from 25 to 
100%  in  different  experiments,  averaging  about  70%.  Also,  these  animals 
showed a slightly greater survival time (median 8 days after adoptive immuni- 
zation). 
Carriers given cells  from normal donors showed much lower mortality, but 
this  varied according to  the  duration  of the  carrier  state  at  the  time  of  cell 
transfer. Transfer 5 days after infection of carriers was followed bv mortality 
TABLE I 
Mortality  after Adoptive Immunization  of LCM-Carrier  Mice with isogenic  Spleen  Cells 
Days from  Mortality for  Days from cell  transfer 
Tvpe of carrier  Spleen  cell dolror  infection to  30 days after  to death 
-  spleen  cell  spleen cell 
transfer  transfer  Median  Range 
Drug-induced adult  Immune  5  42~42  6  5-11 
9  16,/16  6  5-8 
17-25  47,"64  8  4-13 
Normal  5  8/"28  9  8-12 
24  1/29  10 
None*  (5)*  11/124  9  3 19 
(24)*  0/113 
Neonatally infected  Immune  75-138  0/51 
Normal  75  0/11 
*  Drug-induced carriers, held as observed controls; their 30-day mortality was calculated 
from the 5th and 24th days after infection, respectively. 
in  about  one-quarter  of  recipients  (8/28),  somewhat  above that  seen  in  ob- 
served controls (11/124). When carriers were given normal cells  24 days after 
infection, mortality was trivial (1/29), and was similar to that seen in observed 
controls (0/113). 
Neonatal  Carriers.--Neonatal  carriers  were  inoculated  with  LCM  virus 
within 24 hr of birth and given spleen cells  at 75-138 days of age. There was 
no mortality after transfer of cells  from immune or normal donors (Table I). 
The  transferred  cells  were  aliquots  of the  same  suspensions  which  produced 
disease in drug-induced carriers. 
Neuropathological  Observations after Adoptive  Immunization.- 
Drug-induced  carriers:  Drug-induced  carriers  were  adoptively  immunized, 
at 5 and 24 days after infection, and mice were perfused daily. In this experi- 
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cell transfer. In both groups pathological changes were first noted 48 hr before 
death,  but  the  CNS  lesions showed  important  differences  (Table II)  and  are 
described separately. 
Carriers given immune spleen cells 5 days after infection developed a  severe 
TABLE II 
Neuropathological  Lesions  in Mice Inoculated  Intracerebrally  with LCM Virus: Comparison  of 
Natural Disease with That Produced  by Adoptive  Immunization* 
Time from cell transfer to 
sacrifice 
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immune cells on 
PID 75  PID  132 
8 days  17 days:~ 
Normal  Normal 
* LCM only: adult mice inoculated intracerebrally with LCM virus and dying 6-8 days 
later. LCM +  CY  q- immune cells (or q- normal cells): adult mice inoculated with LCM 
virus, given CY 3 days later, and subsequently adoptively immunized with spleen cells from 
immune or normal donors. Neonatal LCM: mice inoculated intracerebrally  with virus within 
24 hr of birth and adoptively immunized  as adults. PID: days from  infection  to adoptive 
immunization. 
:~ See Table IV for viremia and antibody levels in this group of mice. 
§ Inflammatory changes:  --, no lesions seen;  1, trace; 2,  mild; 3,  moderate; 4,  severe. 
Destructive changes: --, no lesions seen; t, less than 1% of area affected;  1, 1-25%; 2, 25- 
50~o; 3, 50-75%; 4, 75-100~.  Median grade is recorded  for each group  of mice, based on 
6-10 animals per group. 
choroiditis (Fig. 1 a)  and leptomeningitis (Fig. 2  a). In comparison with mice 
dying  after  receiving virus  only,  the  inflammatory response was  much  more 
marked,  although  its  evolution  and  composition  was  similar.  The  infiltrate 
first  appeared  in  the  region  of  the  tenia  choroidea  and  gradually spread  to 
involve  the  whole  choroid  plexus.  Cells with  large,  open  nuclei  (presumably 
monocytes)  predominated,  with  a  substantial  minority  (less  than  25%)  of 
polymorphonuclear leukocytes, and small numbers  of lymphocytes. Elsewhere FIG.  1.  (a) Severe choroiditis in an adult mouse inoculated with LCM virus intracerebrally 
(day 0),  treated with CY on day 3, adoptively immunized with isogenic spleen cells from an 
immunized donor on day 5, and perfused when moribund on day 10. Hematoxylin and  erythro- 
sin.  )<  225.  (b)  Apparently normal choroid plexus from a  mouse inoculated with LCM virus 
intracerebrally within 24 hr of birth, adoptively immunized at 8 wk of age with isogenic spleen 
cells from an immunized donor, and perfuseJ 5 days later.  X  225. 
878 FIG.  2.  (a)  Severe leptomeningitis in an  adult  mouse inoculated with LCM  virus intra- 
cerebrally (day 0), treated with CY on day 3, adoptively immunized with isogenic spleen cells 
from an immunized donor on day 5, and perfused when moribund on day 10.  X  500.  (b) Ap- 
parently  normal  leptomeninges  from  a  mouse  inoculated  intracerebrally  with  ]LCM  virus 
within 24 hr of birth, adoptively immunized at 3 wk of age with isogenic spleen cells from an 
immunized donor, and perfused 8 days later.  X  500. 
879 FI6.3.  (a) Olfactory bulb, to show focal necrosis of granule cells, in an adult mouse inocu- 
lated with LCM virus intracerebrally (day 0), treated with CY on day 3, adoptively immunized 
with isogenic spleen cells from an immune donor on day 5, and perfused when moribund on 
day 10.  X  450.  (b) Folium of cerebellum to show necrosis of granule cells, in an adult mouse 
inoculated with LCM  virus intracerebrally (day 0), treated with CY on day 3, adoptively im- 
munized  with isogenic spleen cells from  an  immune  donor  on  day  24,  and  perfused when 
moribund on day 30.  X  125. 
880 FIG 4.  (a)  Cerebellum,  to show focal necrosis involving inner molecular layer,  Purkinje 
cells, and granule cells, with cellular infiltrate in molecular layer. See Fig. 3 b for experimental 
conditions. X  250.  (b) Cerebellum, to show spongy vacuolization of white matter, perivascular 
cuffing, and loci of granule cell necrosis. See Fig. 3 b for experimental conditions. X  225. 
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in the  brain  several  other lesions were seen,  but were relatively mild  and  in- 
frequent.  In  the  olfactory bulbs  of about  half  the  animals  focal granule  cell 
necrosis (Fig. 3 a) and focal spongy changes in the white matter were seen. All 
animals had scattered perivascular cuffs. 
Carriers  given  immune  spleen  cells  24  days  after  infection,  also  developed 
choroiditis and leptomeningitis.  However, this was always relatively mild and 
similar to that seen in mice dying after receiving only an intracerebral injection 
of virus  (Table  II).  Perivascular  inflammation  was  similar  to  that  described 
above. Also, a  few mice had  definite focal softenings of white matter,  usually 
in the pons, and sometimes associated with a perivascular cuff. 
A  striking  constellation  of lesions  was  present  in  the  cerebellums  of these 
mice. The most widespread was focal necrosis of granule  cells,  which involved 
TABLE III 
Virus and Antibody Levds in Drug-Induced  LCM Carriers  after Adoptive  Immunization  with 
Immune or Normal Spleen  Cells* 
Spleen cell donor  Clinical status when  Virus titers  Immunofluores-  cence in choroid  CF titer 
sacrificed  Brain  Plasma  plexus 
Immune  Morbund  5.7  i. 5  4  <  12 
Normal  Normal  5.8  1.6  4  < 12 
None  Normal  6.0  1.8  3  < 6 
* Mice adoptively immunized 5 days after infection and sacrificed 10 days after infection. 
Virus titers  expressed as log10/0.03 g or 0.03 ml, and  immunofluorescence graded  on scale 
where 3 represents  50-75%,  and 4 represents 75-100%  of cells infected. Data are medians 
for three or more mice. 
an estimated  25 %  of the  total  cell population  (Figs.  3  b and 4  b).  Individual 
nuclei  became  pyknotic,  but  did  not  disappear  by the  time  of death.  A  few 
inflammatory cells  were  seen  among necrotic granule  cells.  Common but  less 
widespread was a  spongy softening of the inner molecular layer,  often accom- 
panied by outfall of Purkinje  cells. An infiltrate,  primarily  of monocytes, was 
usually seen  in such  areas  (Fig. 4  a).  Molecular  layer involvement was  often 
contiguous with necrosis of the underlying granule cell stratum.  Finally, most 
animals showed focal softenings of the white matter  of cerebellum,  associated 
in  some  cases  with  perivascular  inflammation  (Fig.  4  b).  After  transfer  of 
spleen  cells  from  normal  isogenic  donors,  drug-induced  carriers  showed  no 
histological  lesions  in  the  CNS  (Table  II),  consistent  with  their  healthy  ap- 
pearance. 
Neonatal  carriers:  Neonatal  carriers  as described above, remained  asympto- 
matic  after transfer of isogenic spleen cells from immune  donors. When sacri- 
ficed 8  and 17  days after cell transfer,  neither choroiditis  (Fig.  1 b)  nor lepto- 
meningitis  (Fig. 2 b)  nor vasculitis was seen in their brains. D.  H.  GILDEN,  G.  A.  COLE,  AND  N.  NATHANSON  883 
Virological and Serological Observations after Cell Transfer.- 
Drug-induced  carriers:  Drug-induced  carriers,  after  receiving  spleen  cells 
from immune donors, were compared with  similar mice given cells from normal 
donors. There was no evidence of a terminal decrease in virus titer in brain or 
plasma or in the immunofluorescent staining of the brain (Table III). Plasmas 
from mice dying  5  days after immune cell  transfer  (10  days  after infection) 
had little or no CF antibody (median  <  1 : 12). 
Neonatal  carriers:  Neonatal  carriers  were  tested  17  days  after  transfer  of 
immune  spleen  cells  (Table  IV).  Viremias, which  were  moderate  to high  in 
untreated carriers (median titer 104 "1 LI)50/0.02 ml) had dropped to trace levels 
in  adoptively immunized  carriers  (median  titer  10°5).  Conversely,  CF  anti- 
body, which  was not  detected  in untreated  carriers,  rose  to very high  levels 
TABLE IV 
Viremia  and CF Antibody  Titers in Neonatcdly Inoculated LCM Carriers: Effect of Adoptive 
Transfer of Immune Spleen Cells* 
Carriers not given  17 days after celt transfer 
cells 
Viremia  Median  4.1  .5 
Range  3.8--4.3  < 0.5-0.7 
CF antibody  Median  < 6  3000 
Range  < 6  200-12,000 
* Adoptively immunized mice received cells 132 days after infection and all animals were 
killed 149 days after infection. Medians based on 3-14 animals. Viremia expressed as logt0 Los0/ 
0.03  ml plasma. 
after  cell  transfer  (median  titer  1:3000).  These  findings,  consistent  with 
Volkert's prior studies (7), documented the efficacy of immune cell transfer  in 
the  same group  of neonatal  carriers  which  failed  to  show  any  CNS  lesions. 
Passive Immunization  with Serum 
A  pool of immune serum was obtained from mice used as donors of spleen 
cells in  adoptive immunization  experiments.  This was  administered to  drug- 
induced  carriers,  5  days after infection,  in  a  single  dose calculated  to give a 
low antibody titer,  similar to that seen in carriers  dying after receipt of im- 
mune spleen cells (Table III).  Table V shows that a low mortality (5/22)  was 
seen after serum transfer, but this was only slightly greater than that  in the 
observed controls (7/51). 
Titers of the donor serum pool and of plasmas of recipients are also shown 
in Table V. Antibody titers in recipients were similar to those predicted by the 
relationship between the volume of administered serum and the volume of the 
plasma compartment. Titers were very similar in viremic and normal recipients, 884  PATHOGENESIS  OF  LYMPtIOCYTIC  CHORIOMENINGITIS.  I[ 
as reported by Volkert (13). The rate of decrease in antibody titer was roughly 
consistent with the 3-5-day half-life of homologous IgG in rodents (14). 
DISCUSSION 
Choriomeningitis  after Adoptive  Immunization.--The  salient  observations  in 
the present study were: (a) Adoptive immunization of CY-induced adult LCM 
carriers  with  spleen  cells  from immune  donors produced  acutely  lethal  CNS 
disease  with  great  regularity,  particularly  when  cells  were transferred  within 
1 wk after infection.  (b)  Cells from nonimmune donors or immune serum had 
little or no effect. (c) Neonatally infected carriers did not develop acute disease 
after adoptive immunization. 
TABLE V 
Mortality  and CF Antibody  Titers after Passive Immunization  of Drug-Induced  Carrier Mice 
with Immune Serum* 
Titer in recipients at indicated 
Type of recipient  Typedonorandserumtiter  of  times after serum  30MortalitYdays  afterf°r 
6 hr  2 days  6 days  serum 
Drug-induced carrier  Immune  6  12  6 
50  6  12  6 
12  25  6 
5/22 
Drug only  Immune  6  6  6 
50  6  6  6 
25  12  6 
0/9 
Drug-induced carrier  None  7/51 
* Sera were administered as a single intravenous dose of 0.25 ml given 5 days after infec- 
tion, to 20-g mice with an estimated  0.8 ml plasma volume. CF titers are given for individual 
animals. 
This  is  the  first  report  of  an  experimental  system  in  which  acutely  fatal 
LCM  can  be  produced  with  regularity  by  transfer  of  lymphoid  cells.  Prior 
studies  of  adoptive  immunization  (3,  7,  8,  10,  ll)  have  utilized  neonatally 
infected  carriers  as  recipients.  The  reports  of Volkert  and  associates  (0,  15) 
indicated that before transfer such recipients had high virus titers in the brain 
and other tissues,  and that grafting of cells from immune donors resulted  in  a 
marked reduction of virus titers  in blood and tissues  over a  period  of 2-4 wk 
with  the  concomitant  appearance  of high  titers  of CF  and  N  antibodies.  No 
clinical  illness  accompanied  these  changes.  Oldstone  and  Dixon  (11)  grafted 
neonatally infected LCM carriers with isogenic immune spleen cells. Depending 
upon  mouse  strain,  minimal  or  no  round  cell  infiltrates  were  produced  in 
leptomeninges  or around vessels,  but none of the recipients  died of acute dis- 
ease  nor  was  choroiditis  reported.  Hotchin  (3,  10)  also  transferred  isogenic D.  H.  GILDEN~  G.  A.  COLE,  AND  N.  NATHANSON  885 
immune  lymphocytes,  thymocytes,  or  bone  marrow  cells,  and  parabiosed 
immune mice to neonatally infected carrier mice. Acute CNS disease was not 
seen,  although virus  suppression was  induced in  some instances.  Our results 
are in essential agreement, in that adoptive immunization of neonatally infected 
carriers with  immune  spleen cells,  sufficient to  suppress  viremia and  induce 
high levels of CF antibody, failed to produce clinical or histological evidence of 
CNS disease. 
Since  the  same  immune  spleen  cells  which  failed  to  produce  disease  in 
neonatal recipients, did produce acutely fatal choriomeningitis in drug-induced 
carriers, it appears that the type of carrier used as a recipient in transfer ex- 
periments  plays  a  critical  role  in  determining  the  subsequent  occurrence of 
disease.  One  important  difference  between  neonatally  induced  and  drug- 
induced carriers is the  distribution  of viral  antigen in the brain.  In neonatal 
carriers, we found (12)  relatively few immunofluorescent antigen-bearing cells 
in the choroid plexus or ependyma, consistent with the reports of Mims  (16) 
and  of  Oldstone  and  Dixon  (17).  Drug-induced  carriers,  in  contrast,  have 
heavy infection of choroid plexus, with 50-100 % of cells antigen-positive, as do 
adult mice dying of acute LCM after intracerebral injection of virus only (12, 
18). This suggests that the choroid plexus of the drug-induced carrier presents 
a more extensive target for the anti-LCM immune response than does that of 
the neonatally induced carrier. 
Another difference between the two types of LCM carriers is the degree of 
extraneural  infection.  Neonatal  carriers  have  much  more widespread  tissue 
infection with higher levels of viremia than do CY-induced carriers. This may 
divert immune lymphoid cells so that fewer reach the choroid plexus as sug- 
gested by studies of delayed hypersensitivity or experimental allergic encepha- 
litis (EAE). 
Desensitization  studies  of  delayed  hypersensitivity  (19)  demonstrated  a 
quantitative  relationship between  the  dose  of desensitizing  antigen  and  the 
subsequent decreased response to graded intradermal doses of antigen. It was 
calculated  that  a  delayed  response  could  be  elicited  when  the  intradermal 
concentration of antigen exceeded the serum concentration by two- to fourfold, 
illustrating the powerful influence of intravascular antigen concentration on the 
local expression of cell-mediated immunity. 
Studies of EAE indicated that immunopathological CNS disease, presumably 
dependent  upon  cell-mediated  immunity,  was  prevented or  suppressed  (20) 
by encephalitogenic basic proteins (BP). Furthermore, it was recently reported 
(21)  that  BP  could interfere with  cellular transfer  of EAE.  When  syngenic 
lymphoid cells from donor rats with  actively induced EAE  were transferred 
intravenously to normal rats, the recipients consistently developed EAE, but 
were  protected if BP  was  injected intravenously shortly  after  adoptive  im- 
munization. 
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mately 100-fold difference in viremia titers between neonatal carriers (10'3-104 
zI)so/0.02  ml)  and drug-induced carriers (10-1(F LD~0) at  the time of immune 
spleen cell  transfer.  Consistent with this view is  the observation that  if CY- 
induced carriers received immune cells  5 days after infection, when they had 
little  if  any viremia,  the  severity of  choroiditis was  much  greater,  survival 
time shorter, and mortality higher than in drug-induced carriers given cells a 
month or more after infection when viremia was always present 02). 
The immunological mechanism of acute choroiditis is illuminated by several 
observations: (a) Immune spleen cells transferred disease with great consistency, 
and the evolving pathology was strikingly similar in its tempo and character to 
classical LCM.  (b)  Antibody was not detectable in mice dying of acute LCM 
and,  likewise,  little  or no  antibody  was  present  in  plasmas  of  carrier  mice 
moribund with LCM after immune spleen cell transfer. Furthermore, staining 
with  fluorescein-conjugated  anti-mouse  immunoglobulin  reveals  few  if  any 
plasma cells and little bound immunoglobulin in the brains of mice with acute 
choroiditis  (G.  A.  Cole  and  N.  Nathanson,  unpublished  observations).  (c) 
Immune  serum  failed  to  produce  acutely  fatal  LCM  when  given  to  drug- 
induced  carriers.  Oldstone  and  Dixon  (11)  injected  neonatal  LCM  carriers 
with immune serum by intravenous or intraspinal  routes. Although they did 
not kill mice or produce convulsions, they did observe histological lesions in the 
CNS.  The salient  features  of these  lesions were  an  initial  appearance  of  an 
acute, sometimes necrotizing polymorphonuclear response gradually resolving 
into a  round cell infiltrate over the following week,  and localization in peri- 
vascular and leptomeningeat areas after intravenous injection. In our view these 
features suggest that Oldstone and Dixon were producing lesions which differed 
significantly  from  the  immunopathology  pathognomonic  of  classical  acute 
LCM.  Since the weight of current evidence indicates that  immune lymphoid 
cells are required for the successful transfer of acute choriomeningitis, it  ap- 
pears likely that the cell-mediated immune response plays a centrol role in the 
pathogenesis of classical LCM disease. 
Cerebellar Necrosis.--The ability of LCM virus to cause cerebellar necrosis 
has now been observed in this laboratory under several curcumstances: (a) in 
young rats, which are not killed by the E-350 strain of LCM, and are left with 
a marked ataxia due to almost total destruction of the cerebellum (22); (b) in 
4-day-old  mice  which  develop  focal  necrosis  before  death  8-12  days  after 
intracerebrat injection (23) ; (c) in adult drug-induced LCM carrier mice adop- 
tively immunized  1 month or more after infection. Furthermore, other mem- 
bers of the arenavirus group appear to produce a similar lesion, as exemplified 
by Tacaribe virus  (24)  and  Tamiami  virus  (D.  H.  Gilden,  unpublished  ob- 
servations) infections of newborn mice. 
The inlmunopathological nature of this lesion is suggested by its occurrence 
after adoptive immunization in the present study. Furthermore, anti-lymphoid 
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mice against Tacaribe-induced cerebellar disease (24). The relative paucity  of 
inflammatory cells in  areas  of granule cell necrosis,  in  comparison  with  the 
marked inflammation of the choroid plexus, raises questions regarding the pre- 
cise mechanism of the cerebellar lesion. This discrepancy is particularly notable 
in the 4-day-old rat where the cerebellum undergoes devastating liquefaction 
in the almost total absence of inflammation apparent in the light microscope 
(22). 
An inconsistency in the relationship between sites of LCM infection in the 
brain and the subsequent localization of necrosis has been repeatedly observed. 
Pathological lesions occur only in areas with moderate to heavy concentrations 
of immunofluorescent antigen,  but  certain regularly infected nuclei are  con- 
sistently uninvolved by subsequent necrosis. In the drug-induced adult carrier, 
immunofluorescent antigen was present in the cerebellum, both in the molecular 
layer and in granule cells, where pathological changes subsequently developed 
However, necrosis was not seen in other parts of the brain, where there were 
infected cells,  with the exception of a  few minimal foci in  the  olfactory bulb. 
This discrepancy is much more dramatic in the 4-day-old mouse and rat, where 
there is widespread infection of the neural parenchyma and necrosis is confined 
to the granule cells of cerebellum (24). The mechanism whereby an immuno- 
pathological process selectively affects a few among many infected CNS nuclei 
is presently unknown. 
SUMMARY 
Lymphocytic choriomeningitis  (LCM)  virus  carriers  were  established  by 
intracerebral inoculation of adult  BALB/c mice followed by a  single dose of 
cyclophosphamide (CY) (150 mg/kg) 3 days after infection, and by intracerebral 
injection within 24 hr of birth. These carriers were then adoptively inmmnized 
with spleen cells or serum from immune or normal BALB/c donors. 
Transfer of immune spleen cells  into drug-induced carriers consistently re- 
sulted  in  acutely  fatal  choriomeningitis,  histologically  strikingly  similar  to 
classical LCM. Normal spleen cells or immune serum failed to produce either 
central  nervous system  (CNS)  pathology or  illness  with  an)"  regularity.  In 
addition, focal necrosis of the cerebellum was seen after adoptive immunization 
of drug-induced carriers but only when mice received cells at least 3 wk after 
inoculation,  which  is  probably explained by the  gradual  spread  of  infection 
from membranes to the neural parenchyma during the first month after estab- 
lishment of the carrier state in adult mice. 
Immune spleen cells, when transferred to neonatal carriers, led to a decrease 
in virus titers in blood and brains  and  to development of antibody without 
acute CNS disease. 
It appears that the production of fatal choriomeningitis after LCM infection 
is determined in part by the distribution of viral antigen, and this is markedly 
different in  neonatal  and  drug-induced  carriers  at  the  time  of cell  transfer. 888  PATHOGENESIS  OF  LYMPtIOCYTIC  CHORIOMENINGITIS.  I[ 
Another factor of potential  importance  is the much higher level of circulating 
viral  antigen  in  the  plasma  of  neonatal  than  in  that  of  drug-induced LCM 
carriers. 
Classical  LCM  disease  can  only be  transferred  by immune  lymphoid cells 
and  not  by  antiserum.  Furthermore,  little  or  no  complement-fixing  (CF) 
antibody was found  in  the  plasma  of mice dying  of acute  choroiditis.  These 
observations  strongly  suggest  that  acute  choroiditis  is  dependent  upon  the 
cell-mediated imnmne response. 
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